Edgewise Therapeutics Stock

edgewisetx.comBioTechFounded: 2017Funding to Date: $65.5MM

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.

Register for Details

For more details on financing and valuation for Edgewise Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Kevin Koch
Chief Executive Officer, President & Board Member
Alan Russell Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Peter Thompson MD
Co-Founder & Chairman
Badreddin Edris Ph.D
Co-Founder & Board Observer

Board Members

Alan Russell Ph.D
Badreddin Edris Ph.D
Jonathan Root MD
US Venture Partners
Kenneth Harrison Ph.D
Novo Holdings
Peter Thompson MD
Robert Jackson MD
Deerfield Management

Other companies like Edgewise Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, closed a $50m Series B financing